Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
Medical Devices & Diagnostics
Pharma & Biotech
AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy
Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.
Medical Devices & Diagnostics
Can PreludeDx and Quanterix turn AidaBREAST into a new standard for radiation therapy decisions
See why AidaBREAST could reshape breast cancer radiation decisions and put spatial proteomics closer to routine oncology use.
Pharma & Biotech
Can Actinium’s ATNM-400 radiotherapy reshape treatment for resistant breast cancer?
Actinium Pharmaceuticals, Inc. has presented new preclinical data for its alpha-particle radiotherapy candidate ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting potent anti-tumor activity across hormone receptor–positive, triple-negative, and therapy-resistant breast cancer models. The findings suggest that ATNM-400 could become a differentiated treatment option for patients with tumors that have progressed after